Oct 27 Bristol-Myers Squibb Co reported better than expected quarterly earnings, fueled by surging sales of its recently approved Opdivo immuno-oncology drug, hepatitis C treatments and its Eliquis blood clot preventer.
The company said it earned $706 million, or 42 cents per share, in the third quarter. That compared with $721 million, or 43 cents per share, in the year-earlier period.
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal15
13:16 Wells Fargo earnings: 96 cents per share, vs. expected EPS of $119
12:02 Bank of America tops earnings forecast, predicts 'significant increase' in net interest income20
11:28 Aabar set to back UniCredit's share sale: sources18